Tymlos 80 MCG dose pen injectr 1.56ML
Ended Awarded
- Contract number
- SPE2DB25FNMWU
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,335
Award facts
- Contract value 100% obligated
- $2,335.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $2,335.13 by the Defense Logistics Agency on September 8, 2025, for the supply of TYMLOS 80 MCG Dose Pen Injector (1.56ML). The contract has no set-aside designation and is scheduled for completion by September 9, 2025, with performance taking place at the company's Park Ridge location. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program, a comprehensive $499,999,999 agreement valid through November 2026 that enables the agency to procure a broad range of pharmaceutical products supporting Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently securing delivery orders for branded and generic prescription drugs, biologics, and medical consumables across diverse therapeutic categories. The company's extensive contract portfolio with DLA demonstrates its capability to provide reliable distribution of specialized pharmaceutical products, including injectable medications and specialty treatments, directly to military health facilities. TYMLOS, an osteoporosis treatment medication, represents the type of specialized pharmaceutical product the company regularly delivers to support the healthcare needs of the Department of Defense.
Quick answers
Who was awarded contract SPE2DB25FNMWU?
SPE2DB25FNMWU was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 8, 2025.
How much is contract SPE2DB25FNMWU worth?
The government has obligated $2,335 on SPE2DB25FNMWU.
Is contract SPE2DB25FNMWU an order under another contract?
Yes. SPE2DB25FNMWU is a delivery order under SPE2DB25D9348, an indefinite delivery contract.
Was contract SPE2DB25FNMWU competed?
The extent of competition for SPE2DB25FNMWU was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award